Cargando…

EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms

One‐year data from EXPLORE Part A showed high disease burden and impaired quality of life (QOL) in patients with acute hepatic porphyria (AHP) with recurrent attacks. We report baseline data of patients who enrolled in EXPLORE Part B for up to an additional 3 years of follow‐up. EXPLORE B is a long‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cassiman, David, Kauppinen, Raili, Monroy, Susana, Lee, Ming‐Jen, Bonkovsky, Herbert L., Thapar, Manish, Guillén‐Navarro, Encarna, Minder, Anna‐Elisabeth, Hale, Cecilia, Sweetser, Marianne T., Ivanova, Aneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825970/ https://www.ncbi.nlm.nih.gov/pubmed/36069414 http://dx.doi.org/10.1002/jimd.12551

Ejemplares similares

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
por: Wang, Bruce, et al.
Publicado: (2022)

An update of clinical management of acute intermittent porphyria
por: Pischik, Elena, et al.
Publicado: (2015)

EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
por: Gouya, Laurent, et al.
Publicado: (2019)

Pathogenesis of acute encephalopathy in acute hepatic porphyria
por: Pischik, Elena, et al.
Publicado: (2023)

Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy
por: Baumann, Katrin, et al.
Publicado: (2022)

Acute Hepatic Porphyrias: Review and Recent Progress
por: Wang, Bruce, et al.
Publicado: (2018)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021)

Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias
por: Besur, Siddesh, et al.
Publicado: (2014)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Benefits of prophylactic heme therapy in severe acute intermittent porphyria
por: Yarra, Pradeep, et al.
Publicado: (2019)

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria
por: Ma, Christopher D., et al.
Publicado: (2022)

Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran—An ongoing clinical conundrum
por: Ma, Christopher D., et al.
Publicado: (2022)

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review
por: Wang, Bruce, et al.
Publicado: (2023)

Acute hepatic porphyria and hepatocellular carcinoma.
por: Kauppinen, R., et al.
Publicado: (1988)

Porphyrin-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated Cell Injury
por: Maitra, Dhiman, et al.
Publicado: (2019)

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
por: Majeed, Chaudry Nasir, et al.
Publicado: (2022)

Case Report: Variegate porphyria disclosed by post-gastric bypass complications and causing predominant painful sensorimotor axonal peripheral neuropathy
por: Collaud, Edwige, et al.
Publicado: (2022)

First Report of a Low-Frequency Mosaic Mutation in the Hydroxymethylbilane Synthase Gene Causing Acute Intermittent Porphyria
por: Belosevic, Adrian, et al.
Publicado: (2023)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients
por: Buendía-Martínez, Juan, et al.
Publicado: (2021)

THE PORPHYRIAS
Publicado: (1981)

Evaluating the Patient Reported Outcomes Measurement Information System Scales in Acute Intermittent Porphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

Acute Porphyria
por: Kernohan, R. J., et al.
Publicado: (1954)

Porphyria revisited.
por: Hurst, L C
Publicado: (1982)

Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework
por: Connolly, Mark P., et al.
Publicado: (2021)

Liver Transplantation because of Acute Liver Failure due to Heme Arginate Overdose in a Patient with Acute Intermittent Porphyria
por: Frei, Pascal, et al.
Publicado: (2012)

Porphyria Cutanea Tarda in a Patient with Myelofibrosis
por: Serrano-Ordóñez, Ana, et al.
Publicado: (2023)

Infectious Mononucleosis and Porphyria
por: Dawson, T. A. J., et al.
Publicado: (1962)

Porphyria and hepatocellular carcinoma
por: Pierach, C.A.
Publicado: (1987)

Acute Hepatic Porphyria
por: Bissell, D. Montgomery, et al.
Publicado: (2015)

Acute intermittent porphyria
por: Syal, Kartik, et al.
Publicado: (2015)

Intermittent Acute Porphyria
por: Macleod, J. G., et al.
Publicado: (1953)

Porphyrias and Mental Handicap
por: Jancar, J.
Publicado: (1978)

Porphyria and kidney diseases
por: Pallet, Nicolas, et al.
Publicado: (2018)

An overview of the cutaneous porphyrias
por: Dawe, Robert
Publicado: (2017)

The Porphyrias: The Royal Purple?
por: Dean, Geoffrey
Publicado: (1970)

Laboratory Diagnosis of Porphyria
por: Di Pierro, Elena, et al.
Publicado: (2021)

High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor
por: Barreda-Sánchez, María, et al.
Publicado: (2019)

PORPHYRIA - A ROYAL MALADY
Publicado: (1968)

Cannot write session to /tmp/vufind_sessions/sess_f314n1fodqli72piqu6alckkd7